In COVID-19 clinical update #45, Daniel Griffin discusses J&J Ad26 vaccine results, reactogenicity after the second dose of mRNA vaccines, expansion of vaccine eligibility, and the finding that encephalitis after SARS-CoV-2 infection is a cytokine release syndrome.
Hosts: Daniel Griffin and Vincent Racaniello
Click arrow to play
Download TWiV 707 (24 MB .mp3, 40 min)
Subscribe (free): iTunes, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode
- J&J Ad26 vaccine phase 1/2 results (NEJM) 7:08
- SARS-CoV-2 encephalitis is a cytokine release syndrome (CID) 25:49
- Letters read on TWiV 707 30:26
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees
Send your questions for Dr. Griffin to firstname.lastname@example.org
Wouldn’t another reason for delaying vaccination for some time after having received the monoclonal be that you don’t want the Spike protein resulting from the vaccine to be consumed by circulating monoclonals before it has a chance to be taken up by the immune system and start to elicit antibody production?
Relatedly, I assume that the half-life of the RNA from the Pfizer & Moderna vaccines is known, and that it’s not more than a day or so, but I don’t recall specifically hearing that.